GN Stock Analysis: GN Store Nord | CO
Medical Devices | CO, Denmark | Market Cap: 16.178m DKK | 12M Return: 15% | DK0010272632 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 42.0M
EPS Trend: -65.6%
Qual. Beats: -2
Rev. Trend: -79.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
GN Store Nord A/S is a Danish company headquartered in Ballerup that operates across three main business segments: Hearing, Enterprise, and Gaming. Founded in 1869, it produces and sells hearing instruments under brands such as ReSound, Beltone, Interton, Danavox, and Jabra Enhance. The Enterprise segment supplies professional audio and video communication devices under the Jabra and BlueParrott brands, while the Gaming segment offers gaming peripherals under the SteelSeries and KontrolFreek brands.
The company serves customers in Denmark, Europe, North America, and other international markets. As a mid-cap stock classified within the Health Care Equipment sub-industry, GN Store Nord combines a traditional medical device business (hearing aids) with adjacent consumer electronics segments in unified communications and gaming hardware, giving it a diversified revenue base across both health care and consumer technology end markets.
- FDA OTC hearing aid rule pressures ReSound and Beltone margins
- SteelSeries gaming revenue growth accelerates on hardware demand
- Jabra Enterprise sales decline as hybrid work demand normalizes
| Net Income: -560.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 3.27 > 1.0 |
| NWC/Revenue: -2.55% < 20% (prev 6.38%; Δ -8.94% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.18b > Net Income -560.0m |
| Net Debt (9.86b) to EBITDA (2.76b): 3.57 < 3 |
| Current Ratio: 0.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (145.6m) vs 12m ago 0.0% < -2% |
| Gross Margin: 35.70% > 18% (prev 54.58%; Δ -18.88% > 0.5%) |
| Asset Turnover: 44.04% > 50% (prev 58.76%; Δ -14.72% > 0%) |
| Interest Coverage Ratio: 0.34 > 6 (EBIT TTM 296.0m / Interest Expense TTM 862.0m) |
| A: -0.01 (Total Current Assets 5.63b - Total Current Liabilities 5.97b) / Total Assets 29.6b |
| B: 0.45 (Retained Earnings 13.4b / Total Assets 29.6b) |
| C: 0.01 (EBIT TTM 296.0m / Avg Total Assets 29.5b) |
| D: 0.53 (Book Value of Equity 10.3b / Total Liabilities 19.3b) |
| Altman-Z'' = 2.03 = BBB |
| DSRI: 0.78 (Receivables 2.99b/5.11b, Revenue 13.0b/17.3b) |
| GMI: 1.53 (GM 54.58% / 35.70%) |
| AQI: 1.21 (AQ_t 0.80 / AQ_t-1 0.66) |
| SGI: 0.75 (Revenue 13.0b / 17.3b) |
| TATA: -0.09 (NI -560.0m - CFO 2.18b) / TA 29.6b) |
| Beneish M = -2.79 (Cap -4..+1) = A |
As of November 06, 2026, the stock is trading at DKK 124.00 with a total of 3,923,310 shares traded. Over the past week, the price has changed by +12.52%, over one month by +15.94%, over three months by +24.67% and over the past year by +14.97%.
Current recommended Stop Loss: 120.30 (which is 3% or 1.2 ATR below the current price).
GN Store Nord has no consensus analysts rating.
P/E Forward = 102.0408
P/S = 0.9826
P/B = 1.5174
P/EG = 2.2348
Revenue TTM = 13.0b DKK
EBIT TTM = 296.0m DKK
EBITDA TTM = 2.76b DKK
Long Term Debt = 8.04b DKK (from longTermDebt, last quarter)
Short Term Debt = 2.44b DKK (from shortTermDebt, last quarter)
Debt = 10.7b DKK (from shortLongTermDebtTotal, last quarter) + Leases 114.0m
Net Debt = 9.86b DKK (calculated: Debt 10.7b - CCE 806.0m)
Enterprise Value = 26.0b DKK (16.2b + Debt 10.7b - CCE 806.0m)
Interest Coverage Ratio = 0.34 (Ebit TTM 296.0m / Interest Expense TTM 862.0m)
EV/FCF = 13.53x (Enterprise Value 26.0b / FCF TTM 1.92b)
FCF Yield = 7.39% (FCF TTM 1.92b / Enterprise Value 26.0b)
FCF Margin = 14.80% (FCF TTM 1.92b / Revenue TTM 13.0b)
Net Margin = -4.31% (Net Income TTM -560.0m / Revenue TTM 13.0b)
Gross Margin = 35.70% ((Revenue TTM 13.0b - Cost of Revenue TTM 8.36b) / Revenue TTM)
Gross Margin QoQ = 49.52% (prev -3.16%)
Tobins Q-Ratio = 0.88 (Enterprise Value 26.0b / Total Assets 29.6b)
Interest Expense / Debt = 8.08% (Interest Expense 862.0m / Debt 10.7b)
Taxrate = 22.32% (204.0m / 914.0m)
NOPAT = 229.9m (EBIT 296.0m * (1 - 22.32%))
Current Ratio = 0.94 (Total Current Assets 5.63b / Total Current Liabilities 5.97b)
Debt / Equity = 1.04 (Debt 10.7b / totalStockholderEquity, last quarter 10.3b)
Debt / EBITDA = 3.57 (Net Debt 9.86b / EBITDA 2.76b)
Debt / FCF = 5.12 (Net Debt 9.86b / FCF TTM 1.92b)
Total Stockholder Equity = 10.5b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.90% (Net Income -560.0m / Total Assets 29.6b)
RoE = -5.35% (Net Income TTM -560.0m / Total Stockholder Equity 10.5b)
RoCE = 1.60% (EBIT 296.0m / Capital Employed (Equity 10.5b + L.T.Debt 8.04b))
RoIC = 0.91% (NOPAT 229.9m / Invested Capital 25.4b)
WACC = 6.94% (E(16.2b)/V(26.8b) * Re(7.38%) + D(10.7b)/V(26.8b) * Rd(8.08%) * (1-Tc(0.22)))
Discount Rate = 7.38% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -52.98 | Cagr: -0.01%
[DCF] Terminal Value 77.97% ; FCFF base≈1.54b ; Y1≈1.76b ; Y5≈2.59b
[DCF] Fair Price = 200.2 (EV 39.0b - Net Debt 9.86b = Equity 29.2b / Shares 145.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -65.65 | EPS CAGR: -35.49% | SUE: -0.98 | # QB: -2
Revenue Correlation: -79.60 | Revenue CAGR: -8.67% | SUE: 0.02 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.75 | Chg30d=+51.86% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=4.05 | Chg30d=+22.83% | Revisions=+0% | GrowthEPS=-9.5% | GrowthRev=-43.1%
EPS next Year (2027-12-31): EPS=4.92 | Chg30d=+1.80% | Revisions=+0% | GrowthEPS=+21.4% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: +25% (up=1, down=0)